# A Study of Intravenously or Subcutaneously Administered REGN3500 in Healthy Adult Subjects

> **NCT02958436** · PHASE1 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 40 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** REGN3500
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02958436
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08
- **Primary completion:** 2017-06-18
- **Final completion:** 2017-10-03
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2017-11-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02958436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02958436, "A Study of Intravenously or Subcutaneously Administered REGN3500 in Healthy Adult Subjects". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02958436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*